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Abstract
Background: Chronic hepatitis B virus (HBV) infection is an important cause of cirrhosis and
hepatocellular carcinoma. The major challenges for current therapies are the low efficacy of
current drugs and the occurrence of drug resistant HBV mutations. RNA interference (RNAi) of
virus-specific genes offers the possibility of developing a new anti-HBV therapy. Recent reports
have shown that lentiviral vectors based on HIV-1 are promising gene delivery vehicles due to their
ability to integrate transgenes into non-dividing cells. Herein, a lentivirus-based RNAi system was
developed to drive expression and delivery of HBV-specific short hairpin RNA (shRNA) in a mouse
model for HBV replication.
Methods: Hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) in the sera of the
mice were analyzed by quantitative sandwich enzyme linked immunosorbent assay (ELISA)
technique, hepatitis B core antigen (HBcAg) and HBsAg in the livers of the mice were detected by
immunohistochemical assay, HBV DNA and HBV mRNA were measured by fluorogenic
quantitative polymerase chain reaction (FQ-PCR) and quantitative real-time PCR respectively.
Results: Co-injection of HBV plasmids together with the lentivirus targeting HBV shRNA induced
an RNAi response. Secreted HBsAg was reduced by 89% in mouse serum, and HBeAg was also
significantly inhibited, immunohistochemical detection of HBcAg or HBsAg in the liver tissues also
revealed substantial reduction. Lentiviral mediated shRNA caused a significant suppression in the
levels of viral mRNA and DNA synthesis compared to the control group.
Conclusion: Lentivirus-based RNAi can be used to suppress HBV replication in vivo, it might
become a potential therapeutic strategy for treating HBV and other viral infections.
Background
Hepatitis B virus (HBV) infection is still a worldwide
health problem. There are an estimated 400 million
chronic HBV infected patients worldwide, especially in
China, where the infection rate is even as high as 9.8%
and over one million people die of liver failure or HBV-
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associated liver cirrhosis and hepatocellular carcinoma
(HCC) annually[1]. Attempts at treatment of chronic
infections have had only limited success. Because of the
low efficacy or side effects of current drugs and the occur-
rence of drug resistant HBV mutations, only about 20% of
the patients benefit from combination therapy with inter-
feron-α and nucleoside analogues such as lamivudine,
entecavir and adefovir dipivoxil [2-6]. Therefore, there is
an urgent need to develop a new therapeutic strategy that
effectively inhibits HBV replication.
The HBV virion comprises an envelope and a nucleocap-
sid containing a circular, partially double-stranded 3.2-kb
DNA, which replicates via an RNA intermediate[7]. Recent
studies have shown that RNA interference (RNAi), which
can be induced in mammalian cells by short hairpin RNAs
(shRNAs), is an evolutionarily conserved surveillance
mechanism that responds to double-stranded RNAs (dsR-
NAs) by sequence-specific post-transcriptional silencing
of homologous genes[8]. It is most important for the
processing of primary miRs, which have important func-
tions for the regulation of gene expression, and thus
inhibits the replication of HBV [9-11]. Synthetic shRNA
duplexes and plasmid-derived shRNAs have been shown
to inhibit HIV-1 infection and replication by specifically
degrading HIV genomic RNA [12-17]. It has also been
shown that shRNA targeting HCV genomic RNA can
inhibit HCV replication[15,18-20]. However, synthetic
shRNAs transfected into target cells can only be retained
for a few days in cells and will be diluted after several gen-
erations of cell division. In many cases, a long-term effect
of RNAi is required. Thus, the selection of transfer vectors
for RNAi has been a focus for RNAi research. To solve this
problem, different alternatively used transfer vehicles,
such as adeno-associated viral vectors(AAV) and adenovi-
ral vectors were also explored for in vivo delivery of shRNA
against HBV infection [21]. Yet, both of them have prom-
inent drawbacks. For example, recombinant AAV will be
lost eventually as it is episomal, and limits their applica-
tion. Retroviral vectors derived from murine leukemia
virus (MuLV) are favourable in gene delivery for their effi-
cient integration into the genome of the target cells and
accompanying expression of the transgenes. However,
these vectors require cell division for efficient gene trans-
fer[22,23]. To circumvent this problem, vector systems
based on the lentivirus genus of retroviruses, which
includes human immunodeficiency virus (HIV), are being
developed[24]. These lentiviral vectors are able to trans-
duce non-dividing cells with sustained long-term expres-
sion of the genes. The majority of target cell types for gene
therapy are non-dividing or slowly dividing, such as hepa-
tocytes[25]. Therefore, these properties of RNAi vector sys-
tems based on HIV or other lentiviruses open up a
possibility of efficiently controlling replication processes
of infectious viruses such as HBV, and have the potential
to become important tools in clinical gene therapy.
In the case of HBV, published in vivo hydrodynamic
transfection studies have shown that simultaneous deliv-
ery of HBV expression plasmids and HBV-specific syn-
thetic shRNA (or ShRNA-expressing constructs) to the
mouse liver can prevent the induction of HBV gene
expression and replication [26-29]. But the possibility of
the inhibition of HBV replication by lentiviral vector
delivery of shRNA has not been systemically studied.
Based on successful establishment of a murine model of
acute HBV infection, in the present study, we selected two
different RNAi target sites of HBV, adopted the hydrody-
namics method, transduced mice hepatocytes with lenti-
viral vectors, and observed the effects of RNAi on the
replication of HBV in animal experiments.
Methods
Plasmids and ShRNA
The vector of pTHBV2 containing the HBV genome plus a
redundancy for the sequences between nt 1067 and 1996
of the HBV genome was donated by Dr. Mc Caffery (Uni-
versity of Iowa, Iowa City, Iowa, USA). Synthetic tran-
scription shRNA template sequences are as follows:
shRNA-1: forward: 5'-CCG GGA GGC GAG GGA GTT CTT
CTT CTA GGG AAG CTT GCC TAG AGG AAG AGC TCC
TTC GCC TCT TTT TG-3'; reverse: 5'-AAT TCA AAA AGA
GGC GAA GGA GCT CTT CCT CTA GGC AAG CTT CCC
TAG AAG AAG AAC TCC CTC GCC TC-3'.shRNA-2: for-
ward: 5'-CCG GGA GGC GAA CAA ATG GCA CTA GTA
AAC TGA GGA AGC TTG CTC AGT TTG CTA GTG TCA
TTT GTT CTT TTT G-3'; reverse: 5'-AAT TCA AAA AGA ACA
AAT GAC ACT AGC AAA CTG AGC AAG CTT CCT CAG
TTT ACT AGT GCC ATT TGT TC-3'. Negative control
shRNA(HBV-irrelevant shRNA): forward: 5'-CCG GGA
GGC AAT CAG TCA ACA CCG TGC ATA TCC AGA AGC
TTG TGG ATA TGC ACG GTG TTG ACT GAT TTT TTT G-
3'; reverse: 5'-AAT TCA AAA AAA TCA GTC AAC ACC GTG
CAT ATC CAC AAG CTT CTG GAT ATG CAC GGT GTT
GAC TGA TT-3'. The expression plasmid pMKO.1-HBV-
ShRNAs (shRNA-1, ShRNA-2 and Negative control
shRNA) were constructed by subcloning above synthetic
annealed duplexes between the AgeI and EcoR I sites of
the plasmid of pMKO.1(Provided by Dr. William Hahn,
Harvard University, USA) respectively. An approximately
300 bp small fragment, including U6 promoter and
shRNA expression cassettes, was digested from pMKO.1-
HBV-shRNA and pMKO.1-Negative control-shRNA by
using Sal I enzyme. The recombinant lentiviral expression
vector pWPT-HBV-shRNA-1, pWPT-HBV-shRNA-2 and
pWPT-Negative control shRNA were constructed by
inserting the 300 bp small fragment into the Sal I site of
pWPT-GFP (provided by Dr. Trono, University of Geneva,
Switzerland) [30].BMC Gastroenterology 2009, 9:73 http://www.biomedcentral.com/1471-230X/9/73
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Lentivirus production and transduction
Recombinant lentivirus was generated from 293T cells (6
× 106 cells/100-mm plate) co-transfected with calcium
phosphate precipitation of 3 plasmids: (1) pWPT-Nega-
tive control-shRNA or pWPT-HBV-shRNAs, and
(2)pCMVΔR8.91, a plasmid expressing the HIV-1 gag/pol,
tat, and rev genes required for efficient lentivirus produc-
tion (gift from D. Trono), and (3) a plasmid expressing
the vesicular stomatitis virus envelope glycoprotein (G),
pLR-VSV-G (Invitrogen Corp. Carlsbad, CA, USA), at
15:15:7.5 μg/plate. Virus was collected and concentrated
500-fold by ultra-high speed centrifugation at 26,000
rpm, 4°C for 2 h, and stocks were stored frozen at -80°C
until used as previously described[31]. Virus titer was
determined by real-time quantitative reverse-tran-
scriptase-PCR measuring copies of proviral DNA inte-
grated into the genome of circulating murine
mononuclear cells as recently described[32]. Replication-
competent virions were confirmed absent from viral
stocks by using extended marker rescue assays. After ultra-
high speed centrifugation, the titers were adjusted to 109
transducing units (TU)/ml.
Experimental animals
Yang and colleagues [33] reported that following hydro-
dynamic transfection of immunocompetent mice with an
HBV plasmid, HBsAg-neutralizing antibodies were
observed, starting at day 7. To avoid complications associ-
ated with neutralizing antibodies, experiments were car-
ried out in NOD SCID mice lacking B and T lymphocytes.
In addition, Park [34] reported that lentiviral vector trans-
duction efficiency and transgene expression were signifi-
cantly enhanced in adolescent (3 1/2 weeks of age) mice
compared to older (7 weeks of age) mice. Thus, for all the
in vivo experiments we used 3-4-week-old female immu-
nocompromised NOD/LtSz-Prkdcscid/J (NOD SCID)
mice (body weights 12-15 g) obtained from the National
Resource Center for Mutant Mice, Model Animal Research
Center of Nanjing University (Nanjing, China). And all
the experiments were approved by the Ethics Committee
of Nanjing Medical University and conducted in accord-
ance with the guidelines approved by the China Associa-
tion of Laboratory Animal Care. The pTHBV2 plasmid
and lentiviral particles carrying shRNAs were delivered
into mouse liver using the hydrodynamic tail vein injec-
tion method, a method that results in gene transfer into 5-
40% of mouse hepatocytes[35,36]. Briefly, 12 μg pTHBV2
was dissolved in 1.6-2.0 ml serum-free medium or lentivi-
rus. And then the medium was steadily and rapidly (no
more than 4 - 6 seconds) injected with high pressure into
the mouse tail vein using a 45-mm scalp needle. The mice
were bled, and the sera were separated and examined for
HBsAg, HBeAg or HBV DNA content on day 1, 4 or 7 after
injection. Samples of mouse livers (5 mm × 6 mm size)
were preserved in 4% paraformaldehyde (PFA) for histo-
logical analysis, while other samples (100-200 mg) were
immediately frozen in liquid nitrogen.
Mice were randomly divided into four groups with six in
each group. According to the materials they would receive
by injection as follows: (i) Empty vector group: 12 μg
pTHBV2 was dissolved in 1.6-2.0 ml serum-free medium.
(ii) pWPT-HBV-shRNA-1 group: 12 μg pTHBV2 was dis-
solved in 1.6-2.0 ml pWPT-HBV-shRNA-1 lentivirus, co-
injected. (iii) pWPT-HBV-shRNA-2 group: 12 μg pTHBV2
was dissolved in 1.6-2.0 ml pWPT-HBV-shRNA-2 lentivi-
rus, co-injected. (iv) Negative control RNAi group: 12 μg
pTHBV2 was dissolved in 1.6-2.0 ml pWPT-Negative con-
trol-shRNA lentivirus, co-injected.
GFP expression in mouse liver
The pTHBV2 plasmid and lentiviral particles carrying GFP
and shRNAs were delivered into mouse liver using the
hydrodynamic tail vein injection method. Mouse livers
were removed from the treated mice 4 or 7 days after len-
tiviral vectors injection respectively and fixed in formalin
prior to embedding into paraffin. Liver sections (5 μm)
were processed for the detection of green fluorescent pro-
tein (GFP) by incubating the tissues with a mouse anti-
GFP monoclonal antibody (sc101525; Santa Cruz Bio-
technology, Santa Cruz, CA, USA) at a dilution of 1:200.
Protein was visualized with the chromogen substrate 3,3-
diaminobenzidine (DAB). Hepatocytes were scored posi-
tive for GFP when clear brown staining of the cytoplasm
could be identified. In each mouse, the GFP stained hepa-
tocytes were determined separately by counting a total of
1500 hepatocytes in 20-30 randomly selected liver fields
(three different liver lobes) and expressed as a percentage
of all positive cells.
Hepatitis B surface antigen (HBsAg) and hepatitis B e 
antigen(HBeAg) ELISA
Blood samples were obtained from the orbital sinus of
experimental animals. Serum HBsAg was determined by a
quantitative sandwich enzyme linked immunosorbent
assay (ELISA) technique, using commercially available
ELISA kits (Abbott). The level of HBeAg in the serum was
measured by sandwich ELISA and quantified relative to a
standard curve of serial dilutions of recombinant HBeAg
(Abbott Laboratories, Abbott Park, IL USA). The relative
concentration of HBeAg was represented by the absorb-
ance value of specimens at 492 nm (A492).
HBsAg and hepatitis B core antigen (HBcAg) expression in 
mouse liver
The formalin-fixed liver tissues samples from the treated
mice were embedded in paraffin. Immunohistochemical
staining for HBsAg and HBcAg was performed using the
PV-6001 kit (Power Vision™ IHC Polymer Detection Rea-
gent, USA) with specific antibodies against HBsAg (rabbit,BMC Gastroenterology 2009, 9:73 http://www.biomedcentral.com/1471-230X/9/73
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OBT0990, Oxford Biotechnology Ltd., Oxford, UK) and
HBcAg (rabbit, Boster Biological Technology, Wuhan,
China). The immunological detection of these antigens
was performed using the manufacturer's protocol.
HBV DNA quantitative PCR analysis
HBV DNA was isolated from mice sera. Fluorescent real-
time polymerase chain reaction (FQ-PCR) was performed
to quantify HBV viral genomic DNA in the mice sera using
an HBV diagnostic kit (PG Biotech, Ltd, Shenzheng,
China) according to the kit's instructions. The primers
specific for the detection of HBV S region were 5'-CCT CTT
CAT CCT GCT GCT-3' and 5'-AAC TGA AAG CCA AAC
AGT G-3'. The fluorescent probe was 5'-FAM-TCC CAT
CCC ATC ATC CTG GGC TTT-TAMRA-3'. The reaction
took place for 40 cycles in the iCycler iQ real-time PCR
system (Bio-Rad Laboratories, USA). The inhibition ratio
of HBV DNA was calculated according to the formula,
which is [1-log(treated sample fluorescent intensity)/
log(control fluorescent intensity)] × 100%.
Quantitative real-time PCR assay
RT reactions were performed using the SuperScript First-
Strand Synthesis System (Invitrogen Co. CA). To deter-
mine the number of cDNA molecules in the reverse tran-
scribed samples, real-time PCR analyses were performed
using the LightCycler system (Roche, IN). PCR was per-
formed using 10 μl 2 × Master Mix SYBR Green I (Takara,
Japan), 0.25 μl of each 5' and 3' primer, and 2 μl samples
or H2O to a final volume of 20 μl. Samples were dena-
tured at 94°C for 5 min. Amplification and fluorescence
determination were carried out in three steps: denatura-
tion at 94°C for 10 sec, annealing at 60°C for 15 sec,
extension at 72°C for 20 sec; and at the end of extension
detection of SYBR Green fluorescence, which reflects the
amount of double-stranded DNA. The amplification cycle
number was 35. To discriminate specific from nonspecific
cDNA products, a melting curve was obtained at the end
of each run. Products were denatured at 95°C for 3 sec,
and the temperature was then decreased to 58°C for 15
sec and raised slowly from 58°C to 95°C using a temper-
ature transition rate of 0.1°C/sec. Data were normalized
with GAPDH levels in the samples. The primer sequences
used for the real-time PCR were listed follows respectively:
forward: 5'-CTG GGT GGG TGT TAA TTT GG-3', reverse:
5'-TAA GCT GGA GGA GTG CGA AT-3' for the HBV C
region; and forward: 5'-ATG GAG AAC ATC ACA TCA GG-
3', reverse: 5'-TTA AAT GTA TAC CCA AAG ACA AAA G-3'
for the HBV S region. The primers for GAPDH (internal
control) were: forward: 5'-AAC TTT GGC ATT GTG GAA
GG-3', reverse: 5'-ACA CAT TGG GGG TAG GAA CA-3'.
(synthesized by Sangon Biological Engineering Technol-
ogy, Shanghai, China).
Statistical analysis
All data are expressed as means ± S.D. The data were based
on six animals per group in vivo. Comparison between
groups was performed by an independent-samples T test.
P-values of less than 0.05 were considered to be statisti-
cally significant.
Results
Selection of RNAi targets sites
According to previous studies [27], two shRNA target
sequences were chosen on the basis of their conservation
among the major HBV genotypes adr, adw, ayr and ayw.
In these cases, the sequences targeted overlapping reading
frames of the virus such that multiple viral RNAs would be
inhibited by one shRNA. Each shRNA targets the prege-
nomic RNA serving as the template for HBV genomic rep-
lication as well as the mRNA for the core antigen and the
polymerase. Moreover, shRNA-1 targets the pregenomic
RNA in the overlap region encoding the core antigen and
the polymerase and shRNA-2 targets the HBV S-antigen
mRNAs (Figure 1).
Immunohistochemical detection of the expression of GFP 
in the liver tissues of mice
The mice were sacrificed on day 4 or 7 after lentiviral vec-
tors hydrodynamic injection. Immunohistochemistry
staining was performed to detect the expression of GFP in
the liver tissues of mice treated with pWPT-GFP-ShRNAs
lentivirus. Consistent with the expected transduction effi-
ciency, each of the lentiviral vectors (pWPT-Negative con-
trol-shRNA or pWPT-HBV-shRNAs) treated mice
exhibited about 11.3 ± 5.1% of positive staining cells of
GFP on day 4 (Figure 2B, 2C, 2D), and showed similar
results on day 7. While GFP was not detectable in the liver
tissue sections in empty vector group(Figure 2A). These
results showed that the lentiviral vectors we used in this
study could transduce hepatocytes in vivo.
Both HBsAg and HBeAg were inhibited by lentiviral 
transduced shRNA targeting HBV
To determine the effect and the minimum concentration
of naked plasmids pTHBV2 for HBV expression in vivo,
the mice were injected via the tail vein with 36 μg, 24 μg,
18 μg or 12 μg pTHBV2, and the levels of serum HBsAg
were 112.21 ± 19.07 (S/N), 105.01 ± 21.66 (S/N), 103.14
± 18.79 (S/N), and 100.54 ± 23.59 (S/N), respectively,
after 1 day (S: the measure value of sample, N: the meas-
ure value of negative control sample; S/N≥2.0 as positive).
Thus, we selected a pTHBV2 concentration of 12 μg
(116.32 ± 19.73 ng/ml), as higher concentrations did not
significantly increase serum HBsAg levels.
The contransfection model was established in which
cotransfection with pTHBV2 and lentiviral particles
pWPT-HBV-shRNA was used to test RNAi response forBMC Gastroenterology 2009, 9:73 http://www.biomedcentral.com/1471-230X/9/73
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Target site and vector information Figure 1
Target site and vector information. (A) Location of RNAi target sites. Downward arrows indicate the location of RNAi 
target sites within the four HBV transcripts. The 3.5-kb transcript is the pregenomic RNA that serves as the template for HBV 
viral DNA replication. The HBV open reading frames are shown below aligned with the HBV mRNAs. Pol: polymerase; Core: 
HBcAg; S1: large pre-surface antigen; S2: middle pre-surface antigen; S: HBsAg; X: X gene. (B) The construction schematic of 
lentiviral vector expressing shRNAs. The shRNA expression cassette, including the U6 pol III promoter, the sense and anti-
sense sequence of the shRNA separated by a 8-base loop, and a terminator composed of six thymidines is inserted directly 
upstream of the CMV promoter of EGFP in the pWPT-GFP vector. Arrows indicate the orientation of transcription for a given 
gene. The putative HBVshRNA-1 and HBVshRNA-2 structures are shown at the bottom.BMC Gastroenterology 2009, 9:73 http://www.biomedcentral.com/1471-230X/9/73
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suppressing HBV antigen production in mice. All experi-
ments were carried out in NOD SCID mice lacking B and
T lymphocytes. Serum HBsAg and HBeAg levels were
measured at day 1, day 4 and day 7.
The results of a timed study showed that there was no sig-
nificant difference in serum HBsAg levels between empty
vector group and Negative control shRNA group on days
1, 4 or 7. In contrast, serum HBsAg levels in pWPT-HBV-
shRNA-1 group were significantly reduced (P < 0.05) on
day 1, 4 and 7 by 54%, 61.8% and 68.1%, and levels in
pWPT-HBV-shRNA-2 group were significantly reduced (P
< 0.05) by 83.9%, 86.8% and 89.9% respectively (Figure
3A). These results convincingly demonstrated that pWPT-
HBV-ShRNA reduced serum HBsAg in mice.
Similar significant results (P < 0.05) were obtained with
the inhibition of serum HBeAg by lentivirus (Figure 3B).
In pWPT-HBV-ShRNA-1 group, the inhibition of serum
HBeAg levels was 35.7%, 39.1% and 44.3% on days 1, 4
and 7, respectively, while the inhibition of serum HBeAg
levels in the pWPT-HBV-ShRNA-2 group at the same time
point was 62.5%, 65.6% and 68.5%, respectively. The
Negative control shRNA group exhibited no suppressive
effect on HBeAg levels, demonstrating the specificity of
shRNA effect.
HBV RNA levels in liver tissue of mice were downregulated 
byusing HBV ShRNA
Real-time PCR analysis was performed to study the inhib-
itory effect of shRNA on viral RNA levels in the livers of
mice. pWPT-HBV-ShRNA-1 treated mice exhibited signif-
icant mean decrease of 82.1% or 53.9% (P < 0.05, Figure
4A) in total levels of HBV S-mRNA, on day 4 or 7, respec-
tively, compared to the untreated control mice. Whereas,
pWPT-HBV-ShRNA-2 treated mice exhibited an average
decrease of 87.5% or 92.9% (P < 0.05, Figure 4A) in HBV
S-mRNA total levels, respectively. In addition, pWPT-
HBV-ShRNA-1 or 2 treated mice exhibited an average
decrease of 80.1%, 63.8% or 84.7%, 96.2% (P < 0.05, Fig-
ure 4B) in total levels of HBV C-mRNA on day 4 or 7
respectively. However, the Negative control RNAi group
had no inhibitory effect.
Immunohistochemistry of the expression of GFP in liver tissue sections Figure 2
Immunohistochemistry of the expression of GFP in liver tissue sections. Lentiviral vectors were injected via tail vein 
by using the hydrodynamic method to the NOD SCID mice, as described in Materials and Methods. On day 4 after injection, 
animals were sacrificed and the livers were embedded and sectioned. Sections were stained immunohistochemically with anti-
mouse GFP monoclonal antibody. The positive staining of GFP expression was detected in numerous liver cells in Negative 
control RNAi group (B), pWPT-HBV-shRNA-1 group (C), and pWPT-HBV-shRNA-2 group (D). A is section from empty vec-
tor group. (400× original magnification, scale bar 50 μm).BMC Gastroenterology 2009, 9:73 http://www.biomedcentral.com/1471-230X/9/73
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Serum HBV antigens levels in HBV shRNA-treated mice Figure 3
Serum HBV antigens levels in HBV shRNA-treated mice. (A) HBsAg levels in NOD SCID mouse sera were signifi-
cantly reduced after treatment with the shRNA expression lentiviral vectors pWPT-HBV-shRNA-1 and shRNA-2. (B) The lev-
els of HBeAg were significantly reduced by treatment with HBV shRNAs in mice. Inhibition of HBV antigens were specific and 
lasted at least 7 days (error bars indicate standard errors). The values showed the average of three experiments (means stand-
ard deviation). The mean value of empty control was defined as 100%. *P < 0.05 vs. the empty vector group. # P > 0.05 vs. the 
empty vector group.
The inhibitory effects on HBV RNA levels by transfection with HBV ShRNAs Figure 4
The inhibitory effects on HBV RNA levels by transfection with HBV ShRNAs. NOD SCID mice were cotransfected 
with 12 μg pTHBV2 and 1.6-2.0 ml pWPT-HBV- ShRNA-1, 2 or negative control shRNA. The mice were sacrificed 4 d and 7 d 
after cotransfection, and hepatocytes RNA was extracted. Each experiment was carried out in triplicate. (A) The total levels of 
HBV S-mRNA in NOD SCID mouse livers were significantly reduced on day 4 or 7 after treatment with pWPT- HBV-shRNA-
1 and shRNA-2 lentivirus. (B) The total levels of HBV C-mRNA were significantly decreased on day 4 or 7 after treatment with 
pWPT-HBV-shRNAs in mice. (error bars indicate standard errors). The values shown were the average of three experiments 
(means standard deviation). The mean value of empty control was defined as 100%. * P < 0.05 vs. the empty vector group. # P 
> 0.05 vs. the empty vector group.BMC Gastroenterology 2009, 9:73 http://www.biomedcentral.com/1471-230X/9/73
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ShRNA-mediated HBV DNA inhibition in vivo
To address this question, the mice sera were harvested and
separated on day 4 and day 7 post-transfection. HBV DNA
was isolated and FQ-PCR analysis was performed with
total serum DNA from treated mice, using an HBV luci-
ferase diagnostic kit (PG Biotech, China). Our results
revealed that both the lentiviral vectors targeting HBV
shRNA significantly suppressed (P < 0.05) HBV viral rep-
lication. The relative copy number of HBV DNA decreased
significantly (P < 0.05) by 68.3% and 62.5% on day 4 and
day 7 respectively in the mice treated by pWPT-HBV-
ShRNA-2. While the inhibitory effect of pWPT-HBV-
ShRNA-1 was 50.1% and 43.6% on day 4 and day 7,
respectively (P < 0.05). The Negative control shRNA had
no significant effect on HBV DNA titers (Figure 5).
Immunohistochemical detection of decreased HBcAg and 
HBsAg expression in the livers of mice
HBsAg, an envelope protein, is secreted into serum fol-
lowing infection. HBcAg, the nucleocapsid protein, is syn-
thesized in infected cells and is required for HBV viral
replication. To histologically determine the effects of ShR-
NAs on HBV antigens, immunohistochemical staining
was conducted. At day 7, paraffin-fixed liver sections were
prepared from the mice in different groups. Consistent
with the expected transduction efficiency, 5.4 ± 1.3% and
5.1 ± 1.2% of cells stained for HBcAg and HBsAg in tissue
sections from mice that only received the plasmid
pTHBV2. Compared with the control group, the percent-
age of HBcAg-positive cells was significantly reduced by
99.1%, and HBsAg-stained cells were scarce in the livers of
pWPT-HBV-ShRNA-2 group. Most fields had no stained
cells, although there were rare hepatocytes with lightly
stained cytoplasm. The percentage of HBcAg or HBsAg-
stained hepatocytes in sections from pWPT-HBV-ShRNA-
1 group was reduced by 92.0% and 84.5% respectively. In
contrast, negative control shRNA group exhibited no
inhibitory effect on the antigens (Figure 6). On the other
hand, no staining was seen in sections from mice that did
not receive pTHBV2 (result not shown). These results
demonstrated that lentiviral vector mediated HBV RNAi
can inhibit the production of HBV proteins.
Discussion
HBV infection, especially chronic HBV infection, is one of
the most common diseases threatening human health.
However, current therapies for chronic HBV infection are
limited. Due to the replication characteristics of HBV,
RNAi has rapidly emerged as a potential gene therapeutic
strategy for HBV infection. First, HBV is a DNA virus; its
replication requires an intermediate pre-genomic RNA
molecule for reverse transcription synthesis of viral DNA.
Therefore, HBV is assumed to be susceptible to RNAi not
only at the level of post-transcription, but also at the level
of replication. Second, the HBV genome is small and its
transcription units are overlapping, which allows the tar-
geting of one site to inhibit multiple HBV mRNAs[37].
Third, the virus replicates almost exclusively in the liver,
an organ that has proved to be accessible to in vivo gene
therapy delivery techniques[38].
Nevertheless, chemically synthesized shRNA delivered to
target cells is known has low and variable transfection effi-
ciency and to be transient, only lasting 3-4 days[39],
which limits the application of ShRNA in long-term gene
silencing in mammalian systems. In order to address this
issue, different viral gene delivery vectors have been
tested. Several studies indicated that the adenovirus or ret-
rovirus mediated RNAi delivery system was an extremely
effective and long-term approach to express shRNA tar-
geted to HBV and could suppress ongoing viral gene
expression and replication in vitro or in vivo[21,40].
However, as adenoviral vectors are episomal, they are not
subject to persistent effects, but are lost upon cell division,
and being a common human pathogen, a large segment of
the general population has pre-existing immunity against
adenoviral proteins. Since retroviruses require cell divi-
sion for integration they are inefficient in transducing
genes into quiescent hepatocytes. In this study we devel-
oped an appropriate lentivirus mediated shRNA delivery
strategy to generate RNAi. Lentiviral vectors are able to
transduce quiescent cells efficiently, including brain, liver,
Serum HBV DNA levels by HBV shRNAs in mice Figure 5
Serum HBV DNA levels by HBV shRNAs in mice. The 
levels of HBV DNA were significantly reduced by treatment 
with pWPT-HBV-shRNA lentivirus. The inhibition of HBV 
DNA was specific (error bars indicate standard errors). The 
mean value of empty control was defined as 100%. * P < 0.05 
vs. the empty vector group. # P > 0.05 vs. the empty vector 
group.BMC Gastroenterology 2009, 9:73 http://www.biomedcentral.com/1471-230X/9/73
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muscle, and hematopoietic stem cells [41-43] with no
apparent requirement for cell proliferation. Some groups
[44-46] have reported that lentiviral vectors can efficiently
deliver shRNA expression cassettes into a variety of cells
with sustained long-term expression and without observ-
able toxicity[47,48]. Although there are lingering
biosafety concerns regarding HIV-1 based lentiviral vec-
tors, the current third-generation replication-defective
and self-inactivating (SIN) lentiviral vectors have mini-
mized the potential risk of generating replication-compe-
tent helper virus[31]. In the present study, we used pWPT-
GFP, a typical third-generation replication-defective SIN
vector, as the transfer vector for shRNA. To our knowl-
edge, this is the first report of the use of this lentivirus
expression system containing a GFP report gene and U6
small nuclear RNA promoter to deliver shRNA into mouse
livers to silence HBV genes.
For a long time, largely due to the narrow host restriction
of HBV and the deficiency of an ideal HBV animal model,
the investigation of HBV infection in vivo was extremely
limited. A hydrodynamics mouse model was reported
[33] that alleviates some of these experimental constraints
and permits HBV to replicate for a period of time. This
type of convenient animal model has been adopted in
some studies in which shRNA was used against
HBV[27,33,35,36,49]. In the present study, we detected
HBV DNA production and HBsAg secretion after hydrody-
namically injecting NOD SCID mice with the HBV
genomic plasmid pTHBV2 via the tail vein.
The design of shRNA is very important in gene silencing.
Based on previous studies[27,49], two shRNA duplexes
targeting the overlap region encoding the core antigen and
the polymerase (POL)/surface antigen region (HBsAg) of
the HBV genome were selected. That is, they both target
the 3.5-kb transcript, which not only serves for translation
of the core protein/HBeAg and polymerase-reverse tran-
scriptase but also represents the template for reverse tran-
scription. In this study, four separate line of evidence
establish that lentivirus mediated delivery of shRNA to the
liver of mice is capable of substantially inhibiting HBV
replication and expression in vivo. Quantitative sandwich
ELISA revealed that HBsAg and HBeAg secreted in mice
sera had been significantly reduced, consistent with the
substantially decreased number of cells staining for
HBcAg or HBsAg (intensity of staining were also
decreased) relative to the controls. Transduction with len-
tiviral vector mediated shRNA resulted in a parallel reduc-
tion of viral DNA synthesis. In addition, real time PCR
analysis demonstrated that the HBV S-mRNA and C-
mRNA levels were significantly reduced in mouse liver.
Immunohistochemical staining for HBsAg (A-D) and HBcAg (E-H) in liver sections Figure 6
Immunohistochemical staining for HBsAg (A-D) and HBcAg (E-H) in liver sections. Treatment with pWPT-HBV-
shRNA-1 lentivirus(C, G) or pWPT-HBV-shRNA-2 lentivirus (D, H) reduces the number of HBsAg or HBcAg-positive cells on 
day 7 respectively compared to the control. The staining was performed on tissue sections from three animals per group. Rep-
resentative sections are shown (four sections per animals were stained and counted). Numerous HBsAg-positive and HBcAg-
positive cells were seen in the empty vector group (A, E) and negative control RNAi group (B, F). No HBsAg-positive stained 
cells were observed in most fields in pWPT-HBV-shRNA-2 group(D). Some stained cells could be seen in pWPT-HBV-shRNA-
1 or shRNA-2 groups(C, G, H) and these were indicated by arrows, but staining were much less intense than that in control 
groups (100× original magnification, scale bar 200 μm).BMC Gastroenterology 2009, 9:73 http://www.biomedcentral.com/1471-230X/9/73
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The present study showed that shRNA-1 also reduced the
levels of HBV S-mRNA and serum HBsAg, even though it
did not directly target the surface antigen gene sequence in
the genome. This result may be due to the inhibiting
effects of the shRNA on the 3.5-kb pregenomic RNA,
reverse transcription template for synthesizing HBV DNA
replication intermediates. Alternatively this result suggests
the possibility of some sequence-independent mecha-
nisms which need to be further studied while ShRNA
exerts its anti-viral effect. McCaffrey et al[27], Wu et al[28],
and Ying et al. [29]also obtained similar results. On the
other hand, similar to results reported by Uprichard et
al[21], we also observed that shRNA mediated suppres-
sion of serum HBeAg was not as dramatic as the suppres-
sion of serum HBsAg. It was suggested that the RNAi
resistance of this subset does not appear to be due to sec-
ondary structure masking of a particular target sequences;
rather, it appears to be due to a more global protection of
a subset of the HBeAg mRNA within RNA-protein com-
plexes, perhaps polyribosome complexes on the rough
endoplasmic reticulum. In addition, our results were sim-
ilar to those reported by McCaffrey et al[27] and Ying et
al[29], except that in our work, the inhibition ratio of HBV
expression and replication were not immediately reduced.
Instead it increased slightly at day 4 and 7 after transduc-
tion of shRNA. It was possibly because the shRNA we
delivered were integrated into the host cell genome, and
could sustain long-term suppression effects. Meanwhile,
the immunocompromised NOD SCID mice, which lack
functional T cells, B cells, and natural killer (NK) cells,
were selected in this experiment, excluding the influence
of complications associated with neutralizing antibodies,
yielding more consistent results.
It is undeniable that using lentiviral vectors expression
system for therapeutic application also has its limitations.
For example, potential insertional mutagenesis may occur
using an integrating viral vector or potential liver damage
due to vector-related toxic side effects that may occur.
Besides, overexpression of hairpins from a U6 promoter
within AAV vectors has been shown to be toxic. Stable
integration of similar cassettes, such as the system which
were used in this study, potentially had any undesirable
effects.
While attempting to develop a different mechanism of
combating HBV infection, Chen et al[26] reported that a
combination of shRNA with lamivudine provided a
greater inhibition of HBV replication. In summary,
although much work remains before making the transi-
tion from using shRNA in a mouse model to the adminis-
tration of shRNA in clinical therapy, our study has shown
that the long-term expression of shRNA mediated by a
lentiviral gene delivery vector might be applicable as a
novel effective gene therapeutic strategy. It could be used
in combination therapy with the nucleoside analogs for
the prevention and treatment of chronic HBV infection,
and for other persistent infections such as HCV and HIV.
The therapeutic potential of shRNAs remains promising.
Conclusion
This study revealed that lentivirus-based RNAi is capable
of inhibiting HBV replication and expression in vivo and
thus may constitute a potential therapeutic strategy for
HBV and other viral infections and provide new clues for
prophylactic vaccine development in the near future.
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